Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Thorac Oncol. 2012 Jun;7(6):947-53. doi: 10.1097/JTO.0b013e31825581bd.

The mTOR pathway in lung cancer and implications for therapy and biomarker analysis.

Author information

  • 1Division of Medical Oncology and Pathology, University of Colorado Denver, Aurora, CO 80045, USA.

Abstract

Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that functions as a key regulatory protein in normal cell growth, survival, metabolism, development, and angiogenic pathways. Deregulation of these processes is a required hallmark of cancer, and dysregulation of mTOR signaling frequently occurs in a wide variety of malignancies, including lung cancer. Targeting of mTOR is thus an attractive strategy in the development of therapeutic agents against lung cancer. In this review, the mTOR-signaling pathway is described, highlighting opportunities for therapeutic intervention and biomarker analysis, and clinical trials in lung cancer including both non-small cell lung cancer and small cell lung cancer.

PMID:
22588151
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk